Toll Free (US/Canada): 1-888-778-7886
Report Code: LS10759
Category : Pharmaceuticals
The global endometrial cancer treatment market is expected to witness growth due to unmet need of treatment, technological advancement in cancer therapeutics and diagnostic test, rising prevalence of cancer, and sedentary lifestyle of women. In addition, increasing awareness about the uterine diseases and the available therapies and increasing healthcare expenditure is also driving the growth of global endometrial cancer treatment market.
The pharmaceutical companies are actively involved in the endometrial cancer research and development. AEterna Zentaris, Inc., is developing Zoptrex (zoptarelin doxorubicin), a Phase III clinical trial drug candidate for the treatment of endometrial cancer. In October 2016, the company entered into licensing agreement with Specialized Therapeutics Asia, a biopharmaceutical company, for the marketing of zoptarelin doxorubicin in Australia and New Zealand.
Endometrial cancer is an abnormal growth of uterus, in which inner lining of the uterus known as endometrium got affected. The American Cancer Society estimated that in year 2016, about 60,050 new cases of endometrial cancer would be diagnosed in the U.S. and about 10,470 women would die from cancers of the uterine body. The sign and symptoms of endometrial cancer is abnormal vaginal bleeding. It is most often diagnosed by pelvic ultrasound and transvaginal ultrasound. An endometrial biopsy is also preferred in postmenopausal women with endometrial cancer.
Certain factors such as high treatment cost, low success rate of clinical trials, side effects of the treatment, high research and development expenditure, and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.
Geographically, North America is expected to be the largest market for endometrial cancer treatment owing to the favorable healthcare infrastructure and government initiatives, increasing number of research and development activities, and high prevalence of endometrial cancer. The U.S. contributed largest revenue to the North American endometrial cancer treatment market and it is expected to remain the largest market globally, during the forecast period.
Some of the key players operating in the global market are Bristol-Myers Squibb Company, Merck & Co., Inc., Ariad Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Eisai Co., Ltd., Exelixis, Inc., F. Hoffmann-La Roche AG, and Abbott Laboratories.
Place An Order